New combo for advanced lung cancer with gene mutations
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs (QL1706 plus chemo and bevacizumab) for people with advanced lung cancer that has a specific gene mutation, has stopped responding to targeted therapy, and has high PD-L1 levels. It aims to see if this approach can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) with a specific gene change (like EGFR, ALK, ROS1, RET, KRAS G12C, BRAF V600, or HER2 insertion).
- Your cancer has gotten worse after at least one previous targeted therapy (TKI pill).
- Your tumor's PD-L1 level is 50% or higher (a lab test confirms this).
- You are between 18 and 75 years old and have good daily function (ECOG 0 or 1).
- You have not had immunotherapy before (like PD-1 or CTLA-4 antibodies).
- You do not have untreated or symptomatic brain metastases, serious heart conditions, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (QL1706 and bevacizumab) with or without chemotherapy for people with advanced non-squamous lung cancer whose cancer worsened after prior immunotherapy. It may offer a new option for those with low PD-L1 levels.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy and a type of high-dose radiation therapy called Quad Shot for people with advanced lung cancer that has no known gene mutations. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.